TITLE

Can modulating corticotropin releasing hormone receptors alter visceral sensitivity?

AUTHOR(S)
Fukudo, S.; Saito, K.; Sagami, Y.; Kanazawa, M.
PUB. DATE
February 2006
SOURCE
Gut;Feb2006, Vol. 55 Issue 2, p146
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Activation of corticotropin releasing hormone (CRH) receptor 2 (CRH-R2) reduces visceral sensitivity induced by colorectal distension in conscious rats. This finding is relevant to the increased interest in the potential use of therapeutic agents that act on CRH receptors in the treatment of irritable bowel syndrome
ACCESSION #
19552420

 

Related Articles

  • CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1 /2 phosphorylation in rats. Million, M.; Wang, L.; Wang, Y.; Adelson, D. W.; Yuan, P-Q.; Maillot, C.; Coutinho, S. V.; Mcroberts, J. A.; Bayati, A.; Mattsson, H.; Wu, V.; Wei, J-Y.; Rivier, J.; Vale, W.; Mayer, E. A.; Taché, V. // Gut;Feb2006, Vol. 55 Issue 2, p172 

    Background and aims: Activation of corticotropin releasing factor 1 (CRF1) receptors is involved in stress related responses and visceral pain, while activation of CRF2 receptors dampens the endocrine and some behavioural stress responses. We hypothesised that CRF2 receptor activation may...

  • The CRF1 Receptor, a Novel Target for the Treatment of Depression, Anxiety, and Stress-Related Disorders. Kehne, John H. // CNS & Neurological Disorders - Drug Targets;2007, Vol. 6 Issue 3, p163 

    The present review focuses on the corticotropin releasing factor type 1 (CRF1) receptor as a novel target for treating depression, anxiety and other stress-related disorders. An organism's stress response system is a complex network of neuronal, endocrine and autonomic pathways which has evolved...

  • Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update. Steckler, Thomas; Dautzenberg, Frank M. // CNS & Neurological Disorders - Drug Targets;2006, Vol. 5 Issue 2, p147 

    Dysfunctioning of corticotropin-releasing factor (CRF) and its receptors (CRF1 and CRF2) has been linked to the development of stress-related disorders, such as affective disorders and drug abuse. The molecular characterization of CRF1 and CRF2 receptors and their splice variants has generated...

  • The Role of Corticotropin-Releasing Hormone in the Pathophysiology of Depression: Therapeutic Implications. Lloyd, R. Brett; Nemeroff, Charles B. // Current Topics in Medicinal Chemistry;Mar2011, Vol. 11 Issue 6, p609 

    Stress responses have been posited to be a key component of mental health and disease by playing essential roles both in normal adaptive processes and maladaptive physiological responses that in part underlie the pathogenesis of certain subtypes of mood and anxiety disorders. Early research...

  • CRF Receptor Antagonists: Utility in Research and Clinical Practice. Chatzaki, E.; Minas, V.; Zoumakis, E.; Makrigiannakis, A. // Current Medicinal Chemistry;2006, Vol. 13 Issue 23, p2751 

    CRF, CRF-related peptides and CRF receptors constitute a complex physiological system which has a key role in facilitating the adaptation of the organism to the stressful stimuli of the environment. The behavioral, endocrine, autonomic and immune branches of stress response are considered to be...

  • Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919). Post, Anke; Ohl, Frauke; Almeida, Osborne F. X.; Binder, Elisabeth B.; Rücker, Monika; Welt, Sandra; Binder, Elke; Holsboer, Florian; Sillaber, Inge // Psychopharmacology;Jun2005, Vol. 180 Issue 1, p150 

    Presents a study which discussed the molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone (CRH) receptor 1 antagonist NBI30775. Role of the neuropeptide CRH; Link between the hyperactivity of the hypothalamic-pituitary-adrenal axis with mood and...

  • Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Licinio, J.; O'Kirwan, F.; Irizarry, K.; Merriman, B.; Thakur, S.; Jepson, R.; Lake, S.; Tantisira, K. G.; Weiss, S. T.; Wong, M.-L. // Molecular Psychiatry;Dec2004, Vol. 9 Issue 12, p1075 

    There are well-replicated, independent lines of evidence supporting a role for corticotropin-releasing hormone (CRH) in the pathophysiology of depression. CRH receptor 1 (CRHR1), which we first mapped in the brain in 1994, has been implicated in the treatment of depression and anxiety. We...

  • Behavioural genetics: Dipsomaniac mice? López, Juan Carlos // Nature Reviews Genetics;Jun2002, Vol. 3 Issue 6, p408 

    Discusses research on the enhanced and delayed stress-induced alcohol drinking in mice lacking functional corticotropin-releasing hormone (CRH). Reference to a study by L. Sillaber and colleagues published in the 2002 issue of "Science" journal; Influence of stress on alcohol intake; CRH...

  • The CRF Receptor Structure, Function and Potential for Therapeutic Intervention. Grigoriadis, D.E.; Haddach, M.; Ling, N.; Saunders, J. // Current Medicinal Chemistry - Central Nervous System Agents;May2001, Vol. 1 Issue 1, p63 

    Two distinct sub-types of receptor encoded by separate genes have been described to date, CRF1 and CRF2, and they belong to the Class-B subdivision within the G-protein coupled receptor (GPCR) super family. All known CRF receptors positively regulate the accumulation of cAMP in response to CRF...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics